Document:

Exhibit 10.5

EXECUTION VERSION

 

BioScrip,
Inc.

1600 Broadway,
Suite 700

Denver,
CO 80202

 

June 29, 2017

 

Undersigned Subscribers

 

Re:Warrant Purchase Agreement

 

Ladies and Gentlemen:

 

We are pleased you
(the “Subscribers” or “you”) have accepted the offer (in connection with the execution and
delivery of the Second Lien Note Purchase Agreement (the “Second Lien Note Purchase Agreement”), the Stock Purchase
Agreement (the “Stock Purchase Agreement”), the Warrant Agreement (the “Warrant Agreement”),
the Registration Rights Agreement (the “Registration Rights Agreement,” and, together with the Second Lien Note
Purchase Agreement, Stock Purchase Agreement and the Warrant Agreement, the “Other Agreements”), each among
BioScrip, Inc., a Delaware corporation (the “Company”), and the other signatories party thereto and of even
date herewith) to purchase warrants (the “Warrants”) to purchase the percentage of the Fully Diluted (as defined
in the Warrant Agreement) common stock of the Company, par value $0.0001 per share (the “Common Stock” or “Shares”)
outstanding on the date of any exercise of such Warrants, such percentage in an amount equal to the number set forth next to your
signature pages below (the “Underlying Shares”). The terms (this “Agreement”) on which the
Subscribers are willing to purchase the Warrants from the Company, and the Company and the Subscribers’ agreements regarding
the sale and purchase of such Warrants, are as follows, it being understood that all obligations, agreements and representations
of the Subscribers under this Agreement are several and not joint:

 

1.                 
Purchase of the Warrants. Subject to satisfaction of the conditions set forth in Section 3.3 hereof, in connection
with the purchase of the Second Lien Notes pursuant to the Second Lien Note Purchase Agreement, the Company agrees to sell the
Warrants to each Subscriber, and each Subscriber hereby agrees to purchase the Warrants from the Company in an amount as set forth
next to such Subscriber’s signature page below, directly or through one or more Affiliates (as hereinafter defined), subject
to the terms and subject to the conditions set forth in this Agreement.

 

2.                 
Representations, Warranties and Agreements.

 

2.1             
Subscribers’ Representations, Warranties and Agreements. To induce the Company to issue the Warrants to each
Subscriber, each Subscriber hereby makes to the Company those representations and warranties set forth in Section 2.30 of the Second
Lien Note Purchase Agreement as if such representations and warranties were set forth in this Agreement, mutatis mutandis, and
made by such Subscriber with reference to and for the purposes of this Agreement.

 

2.2             
Company’s Representations, Warranties and Agreements. To induce the Subscribers to purchase the Warrants, the
Company hereby represents and warrants to the Subscribers and agrees with the Subscribers as follows:

 

     

     

    

 

2.2.1       
Second Lien Note Purchase Agreement representations and warranties. The Company hereby makes to the Subscribers those
representations and warranties set forth in Article IV of the Second Lien Note Purchase Agreement as if such representations and
warranties were set forth in this Agreement, mutatis mutandis, and made by the Company with reference to and for the purposes of
this Agreement.

 

2.2.2       
Title to Warrants. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Warrants will
be duly authorized and validly issued and, when issued, the Underlying Shares will be duly authorized, validly issued, fully paid
and non-assessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof, each Subscriber (or its Affiliates,
as applicable) will have good title to its applicable Warrants and, when issued, the Underlying Shares, free and clear of all liens,
claims, encumbrances, charges, mortgages, options, pledges, security interests, hypothecations, easements, rights-of-way or encroachments
of any nature whatsoever, whether voluntarily incurred or arising by operation of law (“Liens”), other than
(a) transfer restrictions under federal and state securities laws and (b) Liens imposed solely due to the actions of such Subscriber.
Upon issuance in accordance with, and payment pursuant to, the terms hereof, (i) the Warrants and, when issued, the Underlying
Shares, will be issued in accordance with law (including applicable state Blue Sky laws) and the governing documents of the Company
and will not be issued in violation of any preemptive or similar rights created by law or the governing documents of the Company
or any other agreement to which the Company is bound and (ii) the Warrants and, when issued, the Underlying Shares will not be
required to be registered under the Securities Act.

 

2.2.3       
Capitalization. The authorized capital stock of the Company on the date hereof, consists of 250,000,000 shares of
Common Stock, 121,082,543 shares of which are issued and outstanding, 825,000 shares of Series A convertible preferred stock, 21,645
shares of which are issued and outstanding, 825,000 shares of series B convertible preferred stock, no shares of which are issued
and outstanding, 625,000 shares of Series C convertible preferred stock, 614,177 are issued and outstanding and 100,000 shares
of series D junior participating preferred stock, no shares of which are issued and outstanding, and no other capital stock. All
issued and outstanding shares of the Company’s Common Stock (a) have been duly authorized and validly issued, and (b) are
fully paid and non-assessable. The rights, preferences, privileges and restrictions of the Common Stock are as stated in the Certificate
of Incorporation currently on file with the Delaware Secretary of State and the Registration Rights Agreement. Except as set forth
in the periodic reports that the Company has filed on or prior to the date hereof with the U.S.
Securities and Exchange Commission (the “SEC”) (including the exhibits incorporated by reference) in
accordance with its obligations under the Exchange Act and the rules and regulations promulgated thereunder (the “SEC
Reports”), as of the date hereof, no other capital stock, options, units, warrants, rights to purchase (including any
preemptive rights, calls or commitments of any character whatsoever) or otherwise acquire or securities that are exercisable, exchangeable
or convertible into any shares of Common Stock or other ownership interests in the Company are authorized, issued, reserved for
issuance or outstanding (other than herein and pursuant to the Stock Purchase Agreement). Except as set forth in the SEC Reports,
the Company has no authorized or outstanding bonds, debentures, notes or other indebtedness the holders of which have the right
to vote (or which are convertible into, exchangeable for, or evidence the right to subscribe for or acquire securities having the
right to vote) with the holders of capital stock of the Company on any matter. Except as set forth in the SEC Reports, there are
no contracts to which the Company is party or by which it is bound to (x) repurchase, redeem or otherwise acquire any shares
of capital stock of the Company or (y) vote or dispose of any capital stock of the Company. There are no irrevocable proxies
and no voting agreements with respect to any capital stock of the Company. Except as set forth in the SEC Reports, other
than the Registration Rights Agreement, the Company has no agreement, arrangement or understandings to register any securities
of the Company under the Securities Act or under any state securities law and has not granted registration rights to any person
(other than agreements, arrangements or understandings with respect to registration rights that are no longer in effect as of the
date of this Agreement). Immediately following the Closing, and notwithstanding anything contained herein to the contrary, pursuant
to the Warrants the Subscribers will in the aggregate beneficially own 6.34% of the issued and outstanding Common Stock
of the Company on a non-diluted basis and will beneficially own 4.99% of the Fully Diluted Common Stock (as defined in the Warrant
Agreement).

 

    	 	2	 

     

    

 

2.2.4       
SEC Documents. The Company has
timely filed or received the appropriate extension of time within which to file with the SEC all forms, reports, schedules, statements
and other documents required to be filed by it since January 1, 2014 under the U.S. Securities Exchange Act of 1934, as amended,
and the rules promulgated thereunder (the “Exchange Act”) and the Securities Act (such documents, as supplemented
and amended since the time of filing, collectively, the “Company SEC Documents”). The Company SEC Documents,
including any financial statements or schedules included therein, at the time filed (and, in the case of registration statements,
on the dates of effectiveness) (i) did not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading and (ii) complied in all material respects with the applicable requirements
of the Exchange Act and the Securities Act, as the case may be. The financial statements of the Company included in the Company
SEC Documents at the time filed (and, in the case of registration statements, on the dates of effectiveness) were prepared in accordance
with accounting principles generally accepted in the United States of America (“GAAP”) and complied
as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the
SEC with respect thereto during the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited
statements, as permitted by Form 10-Q of the SEC), and fairly present
in all material respects (subject in the case of unaudited statements to normal, recurring audit adjustments) the financial position
of the Company as at the dates thereof and the results of its operations and cash flows for the periods then ended.

 

3.                 
Settlement Date and Delivery.

 

3.1             
Closing. The closing of the purchase and sale of the Warrants hereunder (the “Closing”) shall
be held at the same date and time as, and be conditioned on, the closing of the Other Agreements (the date of the Closing being
referred to as the “Closing Date”). At the Closing, the Company will issue to each of the Subscribers the Warrants,
each registered in the name of such Subscriber, its Affiliate or its permitted assignee (as applicable), against such party’s
performance under the Second Lien Note Purchase.

 

    	 	3	 

     

    

 

3.2             
Conditions to Closing of the Company.

 

The Company’s
obligations to sell and issue the Warrants at the Closing are subject to the fulfillment (or waiver by the Company in writing)
of the following conditions:

 

3.2.1       
Representations. The representations made by the Subscribers in Section 2.1 of this Agreement shall be true and correct
in all material respects when made, and shall be true and correct in all material respects on and as of the Closing Date.

 

3.2.2       
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Subscribers
on or prior to the Closing Date shall have been performed or complied with in all material respects.

 

3.2.3       
No Injunction. There shall not be in force any injunction or order of any court or administrative agency of competent
jurisdiction enjoining or prohibiting the consummation transactions contemplated by this Agreement or the Other Agreements.

 

3.3             
Conditions to Closing of the Subscribers.

 

The Subscribers’
obligation to purchase the Warrants at the Closing is subject to the fulfillment (or waiver by each of the Subscribers in writing)
on or prior to the Closing Date of each of the following conditions:

 

3.3.1       
Representations and Warranties Correct. The representations and warranties of the Company contained in Section 2.2
of this Agreement shall be true and correct in all material respects.

 

3.3.2       
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Company on
or prior to the Closing Date shall have been performed or complied with in all material respects.

 

3.3.3       
Opinion. The Company shall have delivered to the Subscribers an opinion of counsel covering customary matters with
respect to the Warrants and the Underlying Shares.

 

3.3.4       
No Injunction. There shall not be in force any injunction or order of any court or administrative agency of competent
jurisdiction enjoining or prohibiting the consummation transactions contemplated by this Agreement or the Other Agreements.

 

3.3.5       
Conditions to Closing of the Other Agreements. All conditions to the Subscribers’ obligations and the Company’s
obligation to consummate the Other Agreements (as the same is in effect on the date hereof) shall have been satisfied in full or
waived by the party to each of the Other Agreements permitted to waive any such condition, to the extent a Subscriber is a party
to such Other Agreements.

 

3.3.6       
Ancillary Documents. The Subscribers and the Company shall have executed and delivered the Other Agreements, to the
extent a Subscriber is a party to such Other Agreements.

 

    	 	4	 

     

    

 

3.3.7       
Certificates. The Company shall deliver or cause to be delivered to the Subscribers a certificate representing its
applicable Warrants.

 

4.                 
Restrictions on Transfer.

 

4.1             
Securities Law Restrictions. Each Subscriber agrees not to, except to an affiliate of such Subscriber, sell, transfer,
pledge, hypothecate or otherwise dispose of all or any part of the Warrants unless, prior thereto (a) a registration statement
on the appropriate form under the Securities Act and applicable state securities laws with respect to the Warrants proposed to
be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company,
that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules
promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws.

 

4.2             
Restrictive Legends. All certificates representing the Warrants shall have endorsed thereon legends substantially
as follows:

 

“THE SECURITIES REPRESENTED
HEREBY, AND THE SECURITIES ISSUABLE HEREBY, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED
OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH
ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THE COMPANY, IS AVAILABLE.”

 

4.3             
Registration Rights. Subscribers acknowledge that the Warrants are being purchased pursuant to an exemption from
the registration requirements of the Securities Act and the Common Stock underlying the Warrants will become freely tradable only
after certain conditions are met or they are registered pursuant to the Registration Rights Agreement or otherwise.

 

5.                 
Other Agreements.

 

5.1             
Further Assurances.

 

5.1.1       
Each of the Company and each Subscriber agrees to execute such further instruments and to take such further action as may
reasonably be necessary to carry out the intent of this Agreement and to permit the Company to effectuate the Other Agreements.
Each Subscriber and the Company shall each, and shall each cause their
respective affiliates to: (a) assemble, prepare, file and/or submit any information (and to supplement such information) as may
be reasonably necessary to obtain as promptly as practicable all stockholder, governmental and regulatory consents required to
be obtained in connection with the transactions contemplated by this Agreement or the Other Agreements, and (b) use reasonable
best efforts to obtain all consents and approvals of third parties or governmental authorities that the Subscribers, the Company,
or their respective affiliates are required to obtain in order, and to take such other action as may reasonably be necessary or
as another party may reasonably request, to (i) comply with this Agreement and the Other Agreements, (ii) fulfill the conditions
set forth in this Agreement and the Other Agreements and (iii) consummate the transactions contemplated by this Agreement and the
Other Agreements as soon as practicable; provided that, in connection with the exercise of such reasonable best efforts, no party
shall be required to make any payments other than de minimis administrative expenses (and the payment of legal expenses
associated with the consummation of the transactions contemplated herein).

 

    	 	5	 

     

    

 

5.1.2       
Proxy Statement and Other Actions. Promptly following the date hereof, the Company shall prepare and file any necessary
SEC, NASDAQ or New York Stock Exchange filings relating to the issuance of the Warrants to the Subscribers.

 

5.2             
Notices. All notices and other communications to any party herein to be effective shall be in writing and shall be
delivered by hand or overnight courier service, mailed by certified or registered mail, emailed or sent by telecopy, as follows:

 

If to the Company to:

 

BioScrip, Inc.

1600 Broadway, Suite 700

Denver, CO 80202

Attn: Stephen Deitsch, Senior Vice President,

Chief Financial Officer & Treasurer

Email: Stephen.Deitsch@bioscrip.com

Telecopy Number: (720) 468-4040

 

With a copy (which shall not constitute notice) to:

 

Dechert LLP

1095 Avenue of the Americas

New York, New York 10036

Attention: Scott M. Zimmerman

Email: Scott.Zimmerman@dechert.com

Telecopy Number: (212) 698-3599

 

If to a Subscriber, to the address shown next to such
Subscriber’s signature page.

 

With a copy (which shall not constitute notice) to:

 

Paul, Weiss, Rifkind, Wharton & Garrison LLP

Attn: Thomas de la Bastide and Kenneth Schneider

1285 Avenue of the Americas, New York, NY 10019

Email: tdelabastide@paulweiss.com, kschneider@paulweiss.com

Telecopy Number: 212-492-0031, 212-492-0303

 

    	 	6	 

     

    

 

All such notices and
other communications shall be effective upon actual receipt by the relevant Person or, if delivered by overnight courier service,
upon the first business day after the date deposited with such courier service for overnight (next-day) delivery or, if sent by
telecopy, upon transmittal in legible form by facsimile machine or, if mailed, upon the third business day after the date deposited
into the mail or, if delivered by hand, upon delivery or, if emailed, upon receipt by the recipient’s email server if directed
to the email address provided in this Section 5.2.

 

5.3             
Entire Agreement. This Agreement and the Other Agreements constitute the entire agreement among the parties hereto
and thereto and their affiliates regarding the subject matters hereof and thereof and supersede all prior agreements and understandings,
oral or written, regarding such subject matters.

 

5.4             
Modifications and Amendments. The terms and provisions of this Agreement may be modified, supplemented or amended
only by written agreement executed by all parties hereto.

 

5.5             
Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom
granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or
consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement,
whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which
it was given, and shall not constitute a continuing waiver or consent.

 

5.6             
Assignment. The rights and obligations under this Agreement may not be assigned by either party hereto without the
prior written consent of the other party, except to another Subscriber or an affiliate of a Subscriber, and any purported assignment
in violation of the foregoing shall be void ab initio.

 

5.7             
Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding
on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing
in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity
shall be regarded as a third-party beneficiary of this Agreement.

 

5.8             
Governing Law.

 

5.8.1       
This Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Agreement and the transactions contemplated hereby shall be construed in accordance with
and be governed by the law (without giving effect to the conflict of law principles thereof) of the State of New York.

 

5.8.2       
Each party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of
the United States District Court for the Southern District of New York, and of the Supreme Court of the State of New York sitting
in New York county, and of any appellate court from any thereof, in any action or proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby, or for recognition or enforcement of any judgment, and each of the parties hereto
hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined
in such District Court or New York state court or, to the extent permitted by applicable law, such appellate court. Each of the
parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by law.

 

    	 	7	 

     

    

 

5.8.3       
Each party irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue
of any such suit, action or proceeding described in clause 5.8.2 of this Section and brought in any court referred to in clause
5.8.2 of this Section. Each of the parties hereto irrevocably waives, to the fullest extent permitted by applicable law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

5.8.4       
Each party to this Agreement irrevocably consents to the service of process in the manner provided for notices in Section
5.2. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by law.

 

5.9             
WAIVER OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

5.10         
Severability. Any provision of this Agreement held to be illegal, invalid or unenforceable in any jurisdiction, shall,
as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the
legality, validity or enforceability of the remaining provisions hereof; and the illegality, invalidity or unenforceability of
a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

5.11         
No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or
remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right,
power or remedy of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto,
nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other
or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party
hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a
party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further
notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand
to any other or further action in any circumstances without such notice or demand.

 

    	 	8	 

     

    

 

5.12         
No Liability.

 

5.12.1   
Notwithstanding anything that may be expressed or implied in this Agreement or any document or instrument delivered in connection
herewith, the Company, by its acceptance of the benefits of this Agreement, covenants, agrees and acknowledges that no person other
than the Subscribers shall have any obligation hereunder or in connection with the transactions contemplated hereby and that it
has no rights of recovery against, and no recourse hereunder, under any documents or instruments delivered in connection herewith
or in respect of any oral representations made or alleged to be made in connection herewith or therewith, shall be had against,
any former, current or future director, officer, agent, affiliate, manager, assignee or employee of the Investor (or any of their
successors or permitted assignees), against any former, current or future general or limited partner, stockholder, manager or member
of the Subscribers (or any of their successors or permitted assignees) or any affiliate thereof or against any former, current
or future director, officer, agent, employee, affiliate, general or limited partner, stockholder, manager or member of any of the
foregoing (each, other than the Subscribers, an “Affiliate”), whether by the enforcement of any judgment, fine
or penalty or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, or otherwise;
it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on, or otherwise be
incurred by any Affiliate, as such, for any obligations of the Subscribers under this Agreement or the transactions contemplated
hereby, under any documents or instruments delivered in connection herewith, in respect of any oral representations made or alleged
to be made in connection herewith or therewith, or for any claim (whether in tort, contract or otherwise) based on, in respect
of, or by reason of, such obligations or their creation.

 

5.12.2   
The Company further agrees that neither it nor any of its affiliates shall have any right of recovery against any Affiliate
of any Subscriber, whether by piercing of the corporate veil, by a claim on behalf of the Company against the Subscribers or any
of their Affiliates, or otherwise, except to the extent provided in this letter agreement and subject to the terms and conditions
hereof. The Company hereby covenants and agrees that it shall not institute, and shall cause its affiliates not to institute, any
proceeding or bring any other claim (whether in tort, contract or otherwise) arising under, or in connection with, the Agreement
or the transactions contemplated thereby, or in respect of any oral representations made or alleged to be made in connection therewith,
against the Subscribers or any Affiliate other than a claim against a Subscriber relating to the breach of any representation,
warranty or covenant made by the Subscribers herein.

 

5.13         
Survival of Representations and Warranties and Covenants, Obligations and Agreements. All representations and warranties
made by the parties hereto in this Agreement or in any other agreement, certificate or instrument provided for or contemplated
hereby, shall survive the Closing. Any covenant, obligation or agreement to be performed under this Agreement by the Company or
the Subscribers shall survive if ongoing or until fully performed or satisfied.

 

    	 	9	 

     

    

 

5.14         
Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience
of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

5.15         
Counterparts. This Agreement may be executed by one or more of the parties to this Agreement on any number of separate
counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of
an executed counterpart to this Agreement by facsimile transmission or by electronic mail in pdf format shall be as effective as
delivery of a manually executed counterpart hereof.

 

5.16         
Construction. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will
be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa,
unless the context otherwise requires. The words “this Agreement,” “herein,” “hereof,”
“hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and
not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and
covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or
covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the
same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract
from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant. References to
any section, schedule or annex herein shall mean the sections, schedules and annexes of this Agreement.

 

5.17         
Mutual Drafting. This Agreement is the joint product of the Subscribers and the Company and each provision hereof
has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against
any party hereto.

 

5.18         
No Effect on Lender Relationship. The Company (on its behalf and, to the extent possible, on behalf of the stockholders
of the Company) and each Subscriber acknowledges and agrees that, notwithstanding anything in this Agreement or the Warrants to
the contrary, nothing contained in this Agreement or the Warrants shall affect, limit or impair the rights and remedies of any
Subscriber (a) in its or their capacity as a lender or as agent for lenders to the Company or any of its affiliates pursuant to
any agreement under which the Company or any of its affiliates has borrowed money, or (b) in its or their capacity as a lender
or as agent for lenders to any other person who has borrowed money. Without limiting the generality of the foregoing, any such
person, in exercising its rights as a lender, including making its decision on whether to foreclose on any collateral security,
will have no duty to consider (x) its or any of its Affiliates’ status as a holder of Warrants, (y) the interests of the
Company or its affiliates or (z) any duty it may have to any holder of the Company’s equity securities (including any other
holder of Warrants), except as may be required under the applicable loan documents or by commercial law applicable to creditors
generally. No consent, approval, vote or other action taken or required to be taken by the holder of Warrants in such capacity
shall in any way impact, affect or alter the rights and remedies of the Subscriber or any of its Affiliates as a lender or agent
for lenders.

 

5.19         
Non-Promotion. The Company agrees that it will not, without the prior written consent of the affected Subscriber,
in each instance, (a) use in advertising or publicity any name of such Subscriber, or any partner or employee of such Subscriber,
nor any trade name, trademark, trade device, service mark, symbol or any abbreviation, contraction or simulation thereof owned
by such Subscriber, or (b) represent, directly or indirectly, that any product or any service provided by the Company has been
approved or endorsed by such Subscriber.

 

    	 	10	 

     

    

 

5.20         
Use of Logo. The Company grants the Subscribers permission to use any name or logo of the Company or its affiliates
in any marketing materials of the Subscribers. The Subscribers shall include a trademark attribution notice giving notice of the
Company ownership of its trademarks in the marketing materials in which the Company name and logo appear.

 

5.21         
Lock-up Limitations. Notwithstanding anything in this Agreement or the Warrant, none of the provisions of this Agreement
or the Warrant shall in any way limit any Subscriber from engaging in any brokerage, investment advisory, financial advisory,
anti-raid advisory, principaling, merger advisory, financing, asset management, trading, market making, arbitrage, investment
activity and other similar activities conducted in the ordinary course of their business.

 

6.                 
Indemnification and Limitation of Liability. The Company shall indemnify the Subscribers with respect to rights
and obligations under this Agreement under the same terms, mutatis mutandis, as the Company indemnifies Purchasers pursuant to
Section 10.3 of the Second Lien Note Purchase Agreement, and the liability of the Subscribers shall be limited pursuant to the
terms of Section 10.3(e) thereof.

 

7.                 
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid pursuant to the terms of the Commitment Letter, dated as of June 7, 2017, among the Company and the other
signatories party thereto.

 

[Signature
Page Follows]

 

    	 	11	 

     

    

 

If the foregoing accurately
sets forth our understanding and agreement, please sign the enclosed copy of this Agreement and return it to us.

  

	 	Very truly yours,
	 	 	 
	 	BIOSCRIP, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Stephen Deitsch                
	 	Name: 	Stephen Deitsch
	 	Title:	Senior Vice President, Chief Financial Officer and Treasurer

 

 

Signature Page to Warrant Purchase Agreement

 

     

     

    

 

ASSF IV AIV B HOLDINGS, L.P.

as a Subscriber

 

By: ASSF IV AIV B HOLDINGS GP LLC,

its general partner

By: ASSF IV AIV B, L.P.,

its sole member

By: ASSF MANAGEMENT IV, L.P.,

its general partner

By: ASSF MANAGEMENT IV GP LLC,

its general partner

  

 

With respect to Warrants to purchase
3.62909% of the Fully Diluted Common Stock outstanding on the date of any exercise of the Warrants

  

 

	By:	/s/ Scott L. Graves           	 
	Name: 	Scott L. Graves	 
	Title:	Authorized Signatory	 

 

	 	Notice Address:
	 	 
	 	c/o Ares Management LLC
	 	2000 Avenue of the Stars, 12th Floor
	 	Los Angeles, CA 90067

  

 

Signature Page to Warrant Purchase Agreement

 

     

     

    

 

J.P. MORGAN SECURITIES LLC

as a Subscriber

 

 

With respect to Warrants to purchase
0.45364% of the Fully Diluted Common Stock outstanding on the date of any exercise of the Warrants

 

 

	By:	/s/ Jeffrey L. Panzo              	 
	Name: 	Jeffrey L. Panzo	 
	Title:	Attorney in fact	 

 

	 	Notice Address: 
	 	 
	 	J.P. Morgan Securities LLC
	 	4 New York Plaza, 15th Floor, Mail Code NY1-E054
	 	New York, New York 10004
	 	Attention: Jeffrey L. Panzo
	 	Email: Jeffrey.L.Panzo@JPMorgan.com
	 	Phone No.: (212) 499-1435

 

 

Signature Page to Warrant Purchase Agreement

 

     

     

    

 

GOLDMAN SACHS & CO. LLC

as a Subscriber

 

 

With respect to Warrants to purchase
0.68045% of the Fully Diluted Common Stock outstanding on the date of any exercise of the Warrants

 

 

	By:	/s/ Daniel
    Oneglia               	 
	Name: 	Daniel Oneglia	 
	Title:	Managing Director	 

 

	 	Notice Address: 
	 	 
	 	Goldman Sachs & Co. LLC
	 	200 West Street, 26th Floor
	 	Attn: Paul Burningham
	 	New York, New York 10282

 

 

Signature Page to Warrant Purchase Agreement

 

     

     

    

 

Western
Asset Middle Market Debt Fund Inc.

Western
Asset Middle Market Income Fund Inc

each as a Subscriber

 

By: Western Asset Management
Company,

as its Investment Manager and Agent

 

With respect to Warrants to purchase
0.06805% (in the case of Western Asset Middle Market Debt Fund Inc.) and 0.15877% (in the case of Western Asset Middle Market Income
Fund Inc) of the Fully Diluted Common Stock outstanding on the date of any exercise of the Warrants

 

 

	By:	/s/ Adam
    Wright                       	 
	Name: 	Adam Wright	 
	Title:	Manager, U.S. Legal Affairs	 

	 	Notice Address: 
	 	 
	 	J.P. Morgan Securities LLC
	 	4 New York Plaza, 15th Floor, Mail Code NY1-E054
	 	New York, New York 10004
	 	Attention: Jeffrey L. Panzo
	 	Email: Jeffrey.L.Panzo@JPMorgan.com
	 	Phone No.: (212) 499-1435

  

 

Signature Page to Warrant Purchase AgreementExhibit 10.6

EXECUTION VERSION

 

BioScrip,
Inc.

1600 Broadway,
Suite 700

Denver,
CO 80202

 

June 29, 2017

 

ASSF IV AIV B HOLDINGS,
L.P.

 

Re:Stock Purchase Agreement

 

Ladies and Gentlemen:

 

We are pleased you
(the “Subscriber” or “you”) have accepted the offer (in connection with the execution and
delivery of the Second Lien Note Purchase Agreement (the “Second Lien Note Purchase Agreement”), the Warrant
Purchase Agreement (the “Warrant Purchase Agreement”), the Warrant Agreement (the “Warrant Agreement”),
the Registration Rights Agreement (the “Registration Rights Agreement,” and, together with the Second Lien Note
Purchase Agreement, Warrant Purchase Agreement and the Warrant Agreement, the “Other Agreements”), each among
BioScrip, Inc., a Delaware corporation (the “Company”), and the other signatories party thereto and of even
date herewith) to purchase an aggregate number of shares of common stock of the Company, par value $0.0001 per share (the “Common
Stock” or “Shares”), equal to the number set forth next to your signature pages below. The terms (this
“Agreement”) on which the Subscriber is willing to purchase the Shares from the Company, and the Company and
the Subscriber’s agreements regarding such Shares, are as follows:

 

1.
                  Purchase
of the Shares. Subject to satisfaction of the conditions set forth in Section 3.3 hereof, for an amount as set forth next
to the Subscriber’s signature page below, in United States Dollars and in immediately available funds (such amount, the
“Purchase Price”), the Company agrees to sell the Shares to the Subscriber, and the Subscriber hereby
agrees to purchase the Shares from the Company, directly or through one or more Affiliates (as hereinafter defined), subject
to the terms and subject to the conditions set forth in this Agreement.

 

2.                 
Representations, Warranties and Agreements.

 

2.1             
Subscriber’s Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber,
the Subscriber hereby makes to the Company those representations and warranties set forth in Section 2.30 of the Second Lien Note
Purchase Agreement as if such representations and warranties were set forth in this Agreement, mutatis mutandis, and made by the
Subscriber with reference to and for the purposes of this Agreement.

 

2.2             
Company’s Representations, Warranties and Agreements. To induce the Subscriber to purchase the Shares, the
Company hereby represents and warrants to the Subscriber and agrees with the Subscriber as follows:

 

2.2.1       
Second Lien Note Purchase Agreement representations and warranties. The Company hereby makes to the Subscriber those
representations and warranties set forth in Article IV of the Second Lien Note Purchase Agreement as if such representations and
warranties were set forth in this Agreement, mutatis mutandis, and made by the Company with reference to and for the purposes of
this Agreement.

 

     

     

    

 

2.2.2       
Title to Shares. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Shares will be
duly authorized, validly issued, fully paid and non-assessable. Upon issuance in accordance with, and payment pursuant to, the
terms hereof, the Subscriber (or its Affiliates, as applicable) will have good title to the Shares, free and clear of all liens,
claims, encumbrances, charges, mortgages, options, pledges, security interests, hypothecations, easements, rights-of-way or encroachments
of any nature whatsoever, whether voluntarily incurred or arising by operation of law (“Liens”), other than
(a) transfer restrictions under federal and state securities laws and (b) Liens imposed solely due to the actions of the Subscriber.
Upon issuance in accordance with, and payment pursuant to, the terms hereof, (i) the Shares will be issued in accordance with law
(including applicable state Blue Sky laws) and the governing documents of the Company and will not be issued in violation of any
preemptive or similar rights created by law or the governing documents of the Company or any other agreement to which the Company
is bound and (ii) the Shares will not be required to be registered under the Securities Act.

 

2.2.3       
Capitalization. The authorized capital stock of the Company on the date hereof, consists of 250,000,000 shares of
Common Stock, 121,082,543 shares of which are issued and outstanding, 825,000 shares of Series A convertible preferred stock, 21,645
shares of which are issued and outstanding, 825,000 shares of series B convertible preferred stock, no shares of which are issued
and outstanding, 625,000 shares of Series C convertible preferred stock, 614,177 are issued and outstanding and 100,000 shares
of series D junior participating preferred stock, no shares of which are issued and outstanding, and no other capital stock. All
issued and outstanding shares of the Company’s Common Stock (a) have been duly authorized and validly issued, and (b) are
fully paid and non-assessable. The rights, preferences, privileges and restrictions of the Common Stock are as stated in the Certificate
of Incorporation currently on file with the Delaware Secretary of State and the Registration Rights Agreement. Except as set forth
in the periodic reports that the Company has filed on or prior to the date hereof with the U.S.
Securities and Exchange Commission (the “SEC”) (including the exhibits incorporated by reference) in
accordance with its obligations under the Exchange Act and the rules and regulations promulgated thereunder (the “SEC
Reports”), as of the date hereof, no other capital stock, options, units, warrants, rights to purchase (including any
preemptive rights, calls or commitments of any character whatsoever) or otherwise acquire or securities that are exercisable, exchangeable
or convertible into any shares of Common Stock or other ownership interests in the Company are authorized, issued, reserved for
issuance or outstanding (other than herein and pursuant to the Warrant Purchase Agreement). Except as set forth in the SEC Reports,
the Company has no authorized or outstanding bonds, debentures, notes or other indebtedness the holders of which have the right
to vote (or which are convertible into, exchangeable for, or evidence the right to subscribe for or acquire securities having the
right to vote) with the holders of capital stock of the Company on any matter. Except as set forth in the SEC Reports, there are
no contracts to which the Company is party or by which it is bound to (x) repurchase, redeem or otherwise acquire any shares
of capital stock of the Company or (y) vote or dispose of any capital stock of the Company. There are no irrevocable proxies
and no voting agreements with respect to any capital stock of the Company. Except as set forth in the SEC Reports, other
than the Registration Rights Agreement, the Company has no agreement, arrangement or understandings to register any securities
of the Company under the Securities Act or under any state securities law and has not granted registration rights to any person
(other than agreements, arrangements or understandings with respect to registration rights that are no longer in effect as of the
date of this Agreement). Immediately following the Closing, and notwithstanding anything contained herein to the contrary, the
shares of Common Stock issued pursuant to this Agreement will represent 4.99% of the issued and outstanding Common Stock
of the Company on a non-diluted basis.

 

    2 

     

    

 

2.2.4       
SEC Documents. The Company has
timely filed or received the appropriate extension of time within which to file with the SEC all forms, reports, schedules, statements
and other documents required to be filed by it since January 1, 2014 under the U.S. Securities Exchange Act of 1934, as amended,
and the rules promulgated thereunder (the “Exchange Act”) and the Securities Act (such documents, as supplemented
and amended since the time of filing, collectively, the “Company SEC Documents”). The Company SEC Documents,
including any financial statements or schedules included therein, at the time filed (and, in the case of registration statements,
on the dates of effectiveness) (i) did not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading and (ii) complied in all material respects with the applicable requirements
of the Exchange Act and the Securities Act, as the case may be. The financial statements of the Company included in the Company
SEC Documents at the time filed (and, in the case of registration statements, on the dates of effectiveness) were prepared in accordance
with accounting principles generally accepted in the United States of America (“GAAP”) and complied
as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the
SEC with respect thereto during the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited
statements, as permitted by Form 10-Q of the SEC), and fairly present
in all material respects (subject in the case of unaudited statements to normal, recurring audit adjustments) the financial position
of the Company as at the dates thereof and the results of its operations and cash flows for the periods then ended.

 

3.                 
Settlement Date and Delivery.

 

3.1             
Closing. The closing of the purchase and sale of the Shares hereunder (the “Closing”) shall be
held at the same date and time as, and be conditioned on, the closing of the Other Agreements (the date of the Closing being referred
to as the “Closing Date”). At the Closing, the Company will issue to the Subscriber the Shares, each registered
in the name of the Subscriber, its Affiliate or its permitted assignee (as applicable), against delivery of the Purchase Price
in cash on the Closing Date via a wire to an account specified in writing by the Company no later than two (2) business days prior
to the Closing.

 

3.2             
Conditions to Closing of the Company.

 

The Company’s
obligations to sell and issue the Shares at the Closing are subject to the fulfillment (or waiver by the Company in writing) of
the following conditions:

 

3.2.1       
Representations. The representations made by the Subscriber in Section 2.1 of this Agreement shall be true and correct
in all material respects when made, and shall be true and correct in all material respects on and as of the Closing Date.

 

    3 

     

    

 

3.2.2       
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Subscriber
on or prior to the Closing Date shall have been performed or complied with in all material respects.

 

3.2.3       
No Injunction. There shall not be in force any injunction or order of any court or administrative agency of competent
jurisdiction enjoining or prohibiting the consummation transactions contemplated by this Agreement or the Other Agreements.

 

3.3             
Conditions to Closing of the Subscriber.

 

The Subscriber’s
obligation to purchase the Shares at the Closing is subject to the fulfillment (or waiver by the Subscriber in writing) on or prior
to the Closing Date of each of the following conditions:

 

3.3.1       
Representations and Warranties Correct. The representations and warranties of the Company contained in Section 2.2
of this Agreement shall be true and correct in all respects.

 

3.3.2       
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Company on
or prior to the Closing Date shall have been performed or complied with in all material respects.

 

3.3.3       
Opinion. The Company shall have delivered to the Subscriber an opinion of counsel, dated as of the date hereof, covering
customary matters with respect to the Shares.

 

3.3.4       
No Injunction. There shall not be in force any injunction or order of any court or administrative agency of competent
jurisdiction enjoining or prohibiting the consummation transactions contemplated by this Agreement or the Other Agreements.

 

3.3.5       
Conditions to Closing of the Other Agreements. All conditions to the Subscriber’s and the Company’s obligation
to consummate the Other Agreements (as the same is in effect on the date hereof) shall have been satisfied in full or waived by
the party to each of the Other Agreements permitted to waive any such condition, to the extent the Subscriber is a party to such
Other Agreements.

 

3.3.6       
Ancillary Documents. The Subscriber and the Company shall have executed and delivered the Other Agreements, to the
extent the Subscriber is a party to such Other Agreements.

 

3.3.7       
Certificates. The Company shall deliver or cause to be delivered to the Subscriber a book-entry notification, though
American Stock Transfer & Trust Company, LLC, the transfer agent for the Common Stock, evidencing the ownership of the Shares
or a certificate representing the Shares duly endorsed in blank or accompanied by stock powers duly endorsed in blank in proper
form for transfer.

 

    4 

     

    

 

4.                 
Restrictions on Transfer.

 

4.1             
Securities Law Restrictions. Subscriber agrees not to, except to an affiliate of the Subscriber, sell, transfer,
pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration statement on
the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed to be transferred
shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company, that such
registration is not required because such transaction is exempt from registration under the Securities Act and the rules promulgated
by the Securities and Exchange Commission thereunder and with all applicable state securities laws.

 

4.2             
Restrictive Legends. All certificates representing the Shares shall have endorsed thereon legends substantially as
follows:

 

“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES
NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL
FOR THE COMPANY, IS AVAILABLE.”

 

4.3             
Registration Rights. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the
registration requirements of the Securities Act and will become freely tradable only after certain conditions are met or they are
registered pursuant to the Registration Rights Agreement or otherwise.

 

5.                 
Other Agreements.

 

5.1             
Further Assurances.

 

5.1.1       
Each of the Company and Subscriber agrees to execute such further instruments and to take such further action as may reasonably
be necessary to carry out the intent of this Agreement and to permit the Company to effectuate the Other Agreements. The
Subscriber and the Company shall each, and shall each cause their respective affiliates to: (a) assemble, prepare, file and/or
submit any information (and to supplement such information) as may be reasonably necessary to obtain as promptly as practicable
all stockholder, governmental and regulatory consents required to be obtained in connection with the transactions contemplated
by this Agreement or the Other Agreements, and (b) use reasonable best efforts to obtain all consents and approvals of third
parties or governmental authorities that the Subscriber, the Company, or their respective affiliates are required to obtain in
order, and to take such other action as may reasonably be necessary or as another party may reasonably request, to (i) comply with
this Agreement and the Other Agreements, (ii) fulfill the conditions set forth in this Agreement and the Other Agreements and (iii)
consummate the transactions contemplated by this Agreement and the Other Agreements as soon as practicable; provided that, in connection
with the exercise of such reasonable best efforts, no party shall be required to make any payments other than de minimis
administrative expenses (and the payment of legal expenses associated with the consummation of the transactions contemplated herein).

 

    5 

     

    

 

5.1.2       
Proxy Statement and Other Actions. Promptly following the date hereof, the Company shall prepare and file any necessary
SEC, NASDAQ or New York Stock Exchange filings relating to the issuance of the Shares to the Subscriber.

 

5.2             
Notices. All notices and other communications to any party herein to be effective shall be in writing and shall be
delivered by hand or overnight courier service, mailed by certified or registered mail, emailed or sent by telecopy, as follows:

 

If to the Company to:

 

BioScrip, Inc.

1600 Broadway, Suite 700

Denver, CO 80202

Attn: Stephen Deitsch, Senior Vice President,

Chief Financial Officer & Treasurer

Email: Stephen.Deitsch @bioscrip.com

Telecopy Number: (720) 468-4040

 

With a copy (which shall not constitute notice) to:

 

Dechert LLP

1095 Avenue of the Americas

New York, New York 10036

Attention: Scott M. Zimmerman

Email: Scott.Zimmerman@dechert.com

Telecopy Number: (212) 698-3599

 

If to the Subscriber to:

 

ASSF IV AIV B Holdings, L.P.

c/o Ares Management LLC

2000 Avenue of the Stars, 12th Floor

Los Angeles, CA 90067

Attn: Felix
Bernshteyn

Email: felix.bernshteyn@aresmgmt.com

Telecopy Number: (310) 717-6863 

 

With a copy (which shall not constitute notice) to:

 

Paul, Weiss, Rifkind, Wharton & Garrison LLP

Attn: Thomas de la Bastide and Kenneth Schneider

1285 Avenue of the Americas, New York, NY 10019

Email: tdelabastide@paulweiss.com, kschneider@paulweiss.com

Email: 212-492-0031, 212-492-0303

 

    6 

     

    

 

All such notices and
other communications shall be effective upon actual receipt by the relevant Person or, if delivered by overnight courier service,
upon the first business day after the date deposited with such courier service for overnight (next-day) delivery or, if sent by
telecopy, upon transmittal in legible form by facsimile machine or, if mailed, upon the third business day after the date deposited
into the mail or, if delivered by hand, upon delivery or, if emailed, upon receipt by the recipient’s email server if directed
to the email address provided in this Section 5.2.

 

5.3             
Entire Agreement. This Agreement and the Other Agreements constitute the entire agreement among the parties hereto
and thereto and their affiliates regarding the subject matters hereof and thereof and supersede all prior agreements and understandings,
oral or written, regarding such subject matters.

 

5.4             
Modifications and Amendments. The terms and provisions of this Agreement may be modified, supplemented or amended
only by written agreement executed by all parties hereto.

 

5.5             
Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom
granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or
consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement,
whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which
it was given, and shall not constitute a continuing waiver or consent.

 

5.6             
Assignment. The rights and obligations under this Agreement may not be assigned by either party hereto without the
prior written consent of the other party, except to an affiliate of the Subscriber, and any purported assignment in violation of
the foregoing shall be void ab initio.

 

5.7             
Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding
on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing
in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity
shall be regarded as a third-party beneficiary of this Agreement.

 

5.8             
Governing Law.

 

5.8.1       
This Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Agreement and the transactions contemplated hereby shall be construed in accordance with
and be governed by the law (without giving effect to the conflict of law principles thereof) of the State of New York.

 

5.8.2       
Each party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of
the United States District Court for the Southern District of New York, and of the Supreme Court of the State of New York sitting
in New York county, and of any appellate court from any thereof, in any action or proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby, or for recognition or enforcement of any judgment, and each of the parties hereto
hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined
in such District Court or New York state court or, to the extent permitted by applicable law, such appellate court. Each of the
parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by law.

 

    7 

     

    

 

5.8.3       
Each party irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue
of any such suit, action or proceeding described in clause 5.8.2 of this Section and brought in any court referred to in clause
5.8.2 of this Section. Each of the parties hereto irrevocably waives, to the fullest extent permitted by applicable law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

5.8.4       
Each party to this Agreement irrevocably consents to the service of process in the manner provided for notices in Section
5.2. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by law.

 

5.9             
WAIVER OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

5.10         
Severability. Any provision of this Agreement held to be illegal, invalid or unenforceable in any jurisdiction, shall,
as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the
legality, validity or enforceability of the remaining provisions hereof; and the illegality, invalidity or unenforceability of
a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

5.11         
No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or
remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right,
power or remedy of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto,
nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other
or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party
hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a
party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further
notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand
to any other or further action in any circumstances without such notice or demand.

 

    8 

     

    

 

5.12         
No Liability.

 

5.12.1   
Notwithstanding anything that may be expressed or implied in this Agreement or any document or instrument delivered in connection
herewith, the Company, by its acceptance of the benefits of this Agreement, covenants, agrees and acknowledges that no person other
than the Subscriber shall have any obligation hereunder or in connection with the transactions contemplated hereby and that it
has no rights of recovery against, and no recourse hereunder, under any documents or instruments delivered in connection herewith
or in respect of any oral representations made or alleged to be made in connection herewith or therewith, shall be had against,
any former, current or future director, officer, agent, affiliate, manager, assignee or employee of the Investor (or any of their
successors or permitted assignees), against any former, current or future general or limited partner, stockholder, manager or member
of the Subscriber (or any of their successors or permitted assignees) or any affiliate thereof or against any former, current or
future director, officer, agent, employee, affiliate, general or limited partner, stockholder, manager or member of any of the
foregoing (each, other than the Subscriber, an “Affiliate”), whether by the enforcement of any judgment, fine
or penalty or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, or otherwise;
it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on, or otherwise be
incurred by any Affiliate, as such, for any obligations of the Subscriber under this Agreement or the transactions contemplated
hereby, under any documents or instruments delivered in connection herewith, in respect of any oral representations made or alleged
to be made in connection herewith or therewith, or for any claim (whether in tort, contract or otherwise) based on, in respect
of, or by reason of, such obligations or their creation.

 

5.12.2   
The Company further agrees that neither it nor any of its affiliates shall have any right of recovery against the Subscriber
or any of its Affiliates, whether by piercing of the corporate veil, by a claim on behalf of the Company against the Subscriber
or any of its Affiliates, or otherwise, except to the extent provided in this letter agreement and subject to the terms and conditions
hereof. The Company hereby covenants and agrees that it shall not institute, and shall cause its affiliates not to institute, any
proceeding or bring any other claim (whether in tort, contract or otherwise) arising under, or in connection with, the Agreement
or the transactions contemplated thereby, or in respect of any oral representations made or alleged to be made in connection therewith,
against the Subscriber or any Affiliate other than a claim against the Subscriber relating to the breach of any representation,
warranty or covenant made by the Subscriber herein.

 

5.12.3   
Nothing in this Agreement or any of the Other Agreements shall create a fiduciary duty of the Subscriber, or any of its
Affiliates, to the Company or any of its equityholders. The Subscriber is not acting as a financial advisor, agent or underwriter
to the Company. The Subscriber shall to the fullest extent permitted by law have no duty to refrain from (i) engaging in the same
or similar activities or lines of business as the Company or (ii) doing business with any client, customer or vendor of the Company.
If the Subscriber acquires knowledge of a potential transaction or matter that may be a corporate opportunity for both the Company
and the Subscriber or its Affiliates, then each of the Company (on its behalf and, to the extent possible, on behalf of the stockholders
of the Company) to the fullest extent permitted by law renounces any interest or expectancy in such business opportunity and waives
any claim that such business opportunity constituted a corporate opportunity that should have been presented to the Company. In
the case of any such corporate opportunity, the Subscriber shall to the fullest extent permitted by law not be liable to the Company
or its equityholders by reason of the fact that the Subscriber acquires or seeks such corporate opportunity for itself, direct
such corporate opportunity to another person or otherwise does not communicate information regarding such corporate opportunity
to the Company

 

    9 

     

    

 

5.13         
Survival of Representations and Warranties and Covenants, Obligations and Agreements. All representations and warranties
made by the parties hereto in this Agreement or in any other agreement, certificate or instrument provided for or contemplated
hereby, shall survive the Closing. Any covenant, obligation or agreement to be performed under this Agreement by the Company or
the Subscriber shall survive if ongoing or until fully performed or satisfied.

 

5.14         
Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience
of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

5.15         
Counterparts. This Agreement may be executed by one or more of the parties to this Agreement on any number of separate
counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of
an executed counterpart to this Agreement by facsimile transmission or by electronic mail in pdf format shall be as effective as
delivery of a manually executed counterpart hereof.

 

5.16         
Construction. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will
be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa,
unless the context otherwise requires. The words “this Agreement,” “herein,” “hereof,”
“hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and
not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and
covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or
covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the
same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract
from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant. References to
any section, schedule or annex herein shall mean the sections, schedules and annexes of this Agreement.

 

5.17         
Mutual Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof
has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against
any party hereto.

 

    10 

     

    

 

5.18         
No Effect on Lender Relationship. Each of the Company (on its behalf and, to the extent possible, on behalf of the
stockholders of the Company) and the Subscriber acknowledges and agrees that, notwithstanding anything in this Agreement to the
contrary, nothing contained in this Agreement shall affect, limit or impair the rights and remedies of the Subscriber (a) in its
capacity as a lender or as agent for lenders to the Company or any of its affiliates pursuant to any agreement under which the
Company or any of its affiliates has borrowed money, or (b) in its capacity as a lender or as agent for lenders to any other person
who has borrowed money. Without limiting the generality of the foregoing, any such person, in exercising its rights as a lender,
including making its decision on whether to foreclose on any collateral security, will have no duty to consider (x) its or any
of its Affiliates’ status as a holder of the Common Stock, (y) the interests of the Company or its affiliates or (z) any
duty it may have to any holder of the Company’s equity securities (including any other holder of Common Stock), except as
may be required under the applicable loan documents or by commercial law applicable to creditors generally. No consent, approval,
vote or other action taken or required to be taken by the holder of Common Stock in such capacity shall in any way impact, affect
or alter the rights and remedies of the Subscriber or any of its Affiliates as a lender or agent for lenders.

 

5.19         
Non-Promotion. The Company agrees that it will not, without the prior written consent of the Subscriber, in each
instance, (a) use in advertising or publicity any name of any Subscriber, or any partner or employee of the Subscriber, nor any
trade name, trademark, trade device, service mark, symbol or any abbreviation, contraction or simulation thereof owned by such
Subscriber, or (b) represent, directly or indirectly, that any product or any service provided by the Company has been approved
or endorsed by the Subscriber.

 

5.20         
Use of Logo. The Company grants the Subscriber permission to use any name or logo of the Company or its affiliates
in any marketing materials of the Subscriber. The Subscriber shall include a trademark attribution notice giving notice of the
Company ownership of its trademarks in the marketing materials in which the Company name and logo appear.

 

5.21         
Lock-up Limitations. Notwithstanding anything in this Agreement or the Warrant, none of the provisions of this Agreement
or the Warrant shall in any way limit the Subscriber from engaging in any brokerage, investment advisory, financial advisory, anti-raid
advisory, principaling, merger advisory, financing, asset management, trading, market making, arbitrage, investment activity and
other similar activities conducted in the ordinary course of its business.

 

5.22         
Board Observation Rights. During any time that, and only for so long as, the Subscriber or any of its affiliates
holds any debt of the Company or any of its affiliates in an aggregate principal amount of at least $50 million, the Subscriber
shall have the right to appoint one nonvoting board observer (the “Observer”) with respect to the board of directors
of Company or any direct or indirect parent of the Company whose board of directors makes managerial decisions for the Company
and the Guarantors under the notes to be issued under the Second Lien Note Purchase Agreement (the “Board”),
or to any committee thereof, such right to include the right to receive all information and materials provided to the members of
the Board, in their capacity as such, or to any committee thereof, and to attend all regularly scheduled meetings of the Board,
or of any committee thereof; provided that the Observer may be denied access to such meetings and/or materials and information
if and to the extent (i) reasonably necessary to preserve any Board attorney- or accountant-client privilege or (ii) the agenda
for such meeting or such information or materials provided to the Board would result in a breach of confidentiality or would present
a conflict of interest, including, without limitation, any such meeting or information or materials that relate to the notes to
be issued pursuant to the First Lien Notes Purchase Agreement, of even date herewith, or the notes to be issued pursuant to the
Second Lien Note Purchase Agreement. Notwithstanding the foregoing, (i) the Observer shall receive notice promptly in advance of
any meeting of a Board, or any committee thereof, that the Observer is wholly or partially excluded from, and (ii) any written
materials and other information, including portions of the minutes of a meeting of a Board, or any committee thereof, that are
withheld from the Observer, shall specifically and solely relate to the information that the Observer is excluded from and not
any other information. The Observer shall not have any voting rights and shall not be subject to any fiduciary duties applicable
to the directors of the Board. The Observer shall sign a non-disclosure agreement reasonably acceptable to the Subscriber and the
Company.

 

    11 

     

    

 

5.23         
Compliance Assistance. Following the Closing, the Subscriber and the Company shall use reasonable efforts to cooperate
to implement a procedure to assist in the compliance with obligations under Section 13D and Section 16 of the Exchange Act during
such time as the Subscriber or its Affiliates have a Schedule 13D or Schedule 13G on file with the SEC.

 

6.                 
Indemnification and Limitation of Liability. The Company shall indemnify the Subscriber with respect to rights
and obligations under this Agreement under the same terms, mutatis mutandis, as the Company indemnifies Purchasers pursuant to
Section 10.3 of the Second Lien Note Purchase Agreement, and the liability of the Subscriber shall be limited pursuant to the terms
of Section 10.3(e) thereof.

 

7.                 
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid pursuant to the terms of the Commitment Letter, dated as of June 7, 2017, among the Company and the other
signatories party thereto.

 

[Signature
Page Follows]

 

    12 

     

    

 

If the foregoing accurately
sets forth our understanding and agreement, please sign the enclosed copy of this Agreement and return it to us.

 

	 	Very truly yours,
	 	 	 
	 	BIOSCRIP, INC.
	 	 	 
	 	 	 
	 	By:	/s/
Stephen Deitsch
	 	Name: 	Stephen
Deitsch
	 	Title:	Senior
Vice President, Chief Financial Officer and Treasurer

 

    
Signature Page to Stock Purchase Agreement

     

    

 

Accepted and agreed this 29th day of June, 2017.

 

ASSF IV AIV B HOLDINGS II, L.P.

as a Purchaser

 

		By:	ASSF IV AIB B HOLDINGS GP LLC,

its General Partner

		By:	ASSF IV AIV B, L.P.,

its Sole Member

		By:	ASSF MANAGEMENT IV, L.P.,

its General Partner

		By:	ASSF MANAGEMENT IV GP LLC,

its General Partner

 

	 	With respect to 6,359,350 shares of Common Stock	 
	 	For an aggregate Purchase Price of $15,898,375.	 
	 	 	 
	By:	/s/ Scott L. Graves	 
	Name:	Scott L. Graves	 
	Title:	Authorized Signatory	 

  

    
Signature Page to Stock Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]